Celltrion Extends Remsima SC Indications
Subcutaneous Infliximab Gets Nod Covering IBD And Ankylosing Spondylitis
Executive Summary
Celltrion has received a positive opinion from the CHMP for five additional indications for its Remsima SC biosimilar, expanding the scope of the subcutaneous infliximab product that was launched earlier this year.
You may also be interested in...
Celltrion Sets Out Plans To Trial Coronavirus Treatments
In an exclusive interview with Generics Bulletin, Celltrion Healthcare’s UK commercial director, Matt Eddleston, has set out the firm’s plans to roll out an antibody test and trial two antiviral treatments for COVID-19. Meanwhile, the company’s recently-launched subcutaneous version of biosimilar infliximab, Remsima SC, is helping to free up hospital space in the UK by allowing treatment to be moved out of that setting as the coronavirus pandemic progresses.
Celltrion Launches Remsima SC In UK
Celltrion has launched Remsima SC in the UK. Meanwhile, the innovative subcutaneous version of biosimilar infliximab has also received approval in Korea.
Podcast: Celltrion’s Subcutaneous Infliximab And The Future Of Biosimilars
In this podcast discussion, Generics Bulletin’s David Wallace talks to Informa Pharma Consulting’s Duncan Emerton about Celltrion’s CHMP nod for subcutaneous Remsima, the product’s imminent approval and launch, and what it means for the future of biosimilars.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: